CDK4 and cancer: Combination of CDK4/6 inhibitors and immunotherapy is another strategy to induce anti-cancer immune responses by using anti-PD-1/PD-L1 inhibitors (Deng et al., 2018; Schaer et al., 2018; Yuan et al., 2021).